These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2324790)

  • 1. Prescription-event monitoring: methodology and recent progress.
    Rawson NS; Pearce GL; Inman WH
    J Clin Epidemiol; 1990; 43(5):509-22. PubMed ID: 2324790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing studies: the work of the Drug Safety Research Unit.
    Mackay FJ
    Drug Saf; 1998 Nov; 19(5):343-53. PubMed ID: 9825948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.
    Key C; Layton D; Shakir SA
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):143-8. PubMed ID: 11998539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terminology in prescription-event monitoring.
    Kubota K; Inman WH
    Eur J Clin Pharmacol; 1994; 46(6):497-500. PubMed ID: 7995314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
    Boshier A; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2003 Dec; 59(10):767-73. PubMed ID: 14615857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription-event monitoring in Japan (J-PEM).
    Kubota K
    Drug Saf; 2002; 25(6):441-4. PubMed ID: 12071781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription-event monitoring--recent progress and future horizons.
    Mann RD
    Br J Clin Pharmacol; 1998 Sep; 46(3):195-201. PubMed ID: 9764958
    [No Abstract]   [Full Text] [Related]  

  • 12. Prescriber profile and post-marketing surveillance.
    Inman W; Pearce G
    Lancet; 1993 Sep; 342(8872):658-61. PubMed ID: 8103150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
    Perrio MJ; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(8):681-95. PubMed ID: 17696581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database.
    Clark DW; Layton D; Wilton LV; Pearce GL; Shakir SA
    Drug Saf; 2001; 24(15):1143-54. PubMed ID: 11772147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies.
    Wilton LV; Pearce GL; Mann RD
    Br J Clin Pharmacol; 1996 Apr; 41(4):277-84. PubMed ID: 8730972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management.
    Layton D; Hazell L; Shakir SA
    Drug Saf; 2011 Dec; 34(12):e1-9. PubMed ID: 22077508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription-event monitoring. A preliminary study of benoxaprofen and fenbufen.
    Inman WH
    Acta Med Scand Suppl; 1984; 683():119-26. PubMed ID: 6234753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
    Kasliwal R; Wilton LV; Cornelius V; Aurich-Barrera B; Shakir SA
    Drug Saf; 2007; 30(2):157-70. PubMed ID: 17253880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.